 |
|
Duration of Antiviral Prophylaxis During Nursing Home Outbreaks of Influenza A
A Comparison of 2 Protocols
Paul J. Drinka, MD;
Stefan Gravenstein, MD;
Margo Schilling, MD;
Peggy Krause, RN;
Barbara A. Miller, RN;
Peter Shult, PhD
Arch Intern Med. 1998;158:2155-2159.
Background We performed a randomized trial of 2 protocols guiding the duration of antiviral chemoprophylaxis during outbreaks of influenza A in a rural, 700-bed nursing home for veterans and their spouses with 14 nursing units in 4 buildings.
Methods Half of all residents volunteered to participate. Nursing units were randomized, and the effectiveness of short-term (minimum, 14 days and 7 days without the onset of a case in the building) vs long-term (minimum, 21 days and 7 days without the onset of a case in the 4-building facility) prophylaxis was compared using amantadine hydrochloride in the influenza seasons of 1991-1992 and 1993-1994 and rimantadine hydrochloride in the influenza season of 1994-1995. A "case" is defined as an incident of a respiratory tract illness and the isolation of an influenza virus organism. We compared the number of cases after the discontinuation of short vs long-term chemoprophylaxis. Prospective surveillance identified residents with new respiratory tract symptoms, and specimens for viral cultures were obtained even in the absence of temperature elevation.
Results We documented influenza A virus activity during 3 seasons (32, 68, and 12 patients, respectively). During the 1991-1992, 1993-1994, and 1994-1995 influenza seasons, the patients on 11 floors were assigned to receive short-term chemoprophylaxis and those on 10 floors were assigned to long-term chemoprophylaxis. Only in 1993-1994 did chemoprophylaxis extend beyond 14 or 21 days when new cases continued beyond 14 days. Amantadine-resistant strains were circulating at that time. None of the participants in the prospective, controlled study had influenza develop after the termination of short- or long-term chemoprophylaxis.
Conclusion Antiviral chemoprophylaxis can be administered for the longer duration of 14 days or, in the absence of new culture-confirmed illness in the nursing building, for 7 days.
From the Office of the Medical Director (Dr Drinka) and the Research Institute (Ms Krause), Wisconsin Veterans Home, King; the Department of Internal Medicine–Geriatrics (Dr Drinka) and the Institute on Aging and Adult Life (Ms Miller), University of Wisconsin School of Medicine, Madison; the Department of Internal Medicine–Geriatrics, Glennan Center for Geriatrics and Gerontology, Eastern Virginia Medical School, Norfolk (Drs Gravenstein and Schilling); and Communicable Diseases Division, State Laboratory of Hygiene, Madison, Wis (Dr Shult).
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Prevention and Treatment of Influenza
Couch
NEJM 2000;343:1778-1787.
FULL TEXT
|
